Resonance tests FerriScan

By Dylan Bushell-Embling
Tuesday, 01 July, 2008

WA-based diagnostics company Resonance Health (ASX: RHT) has lodged an application with the Australian Medical Services Advisory Committee seeking reimbursement for its FerriScan iron test in Australia.

The company has already had some public funding success overseas, with the Whittington Hospital in London receiving funding approval from the British National Health Service [NHS].

FerriScan is used in to test for and measure levels of iron overload in the liver, caused by regular blood transfusions received by patients with sickle cell disease, thalassemia major and myelodysplastic syndromes.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd